{"id":4013,"date":"2025-06-27T12:29:23","date_gmt":"2025-06-27T09:29:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4013"},"modified":"2025-06-27T12:29:24","modified_gmt":"2025-06-27T09:29:24","slug":"entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies\/","title":{"rendered":"Entrada Therapeutics inicia ensaios cl\u00ednicos na Europa para terapias de salto de exon 44 e exon 45"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Entrada Therapeutics lan\u00e7ou oficialmente os testes cl\u00ednicos na Europa para suas terapias inovadoras de salto de exon visando o exon 44 e o exon 45, marcando um marco significativo no tratamento da distrofia muscular de Duchenne (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Essas terapias experimentais s\u00e3o projetadas para tratar muta\u00e7\u00f5es gen\u00e9ticas espec\u00edficas em pacientes com DMD, com o objetivo de restaurar a produ\u00e7\u00e3o de distrofina e melhorar os desfechos cl\u00ednicos. O in\u00edcio desses ensaios cl\u00ednicos destaca o compromisso do Entrada com o avan\u00e7o da medicina gen\u00e9tica de precis\u00e3o e a expans\u00e3o do acesso global a novos tratamentos para doen\u00e7as neuromusculares raras. \u2013 Leia mais: <a href=\"https:\/\/dmdwarrior.com\/pt\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" rel=\"noreferrer noopener\">O que \u00e9 Exon Skipping e como funciona?<\/a> \u2013<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u00cdndice<\/h2><nav><ul><li><a href=\"#entrada-exon-44-skipping-nct-07037862\">Entrada Exon 44 pulando \u2013 NCT07037862 \u2013<\/a><\/li><li><a href=\"#entrada-exon-45-skipping-nct-07038824\">Entrada Exon 45 pulando \u2013 NCT07038824 \u2013<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-44-skipping-nct-07037862\">Entrada Exon 44 pulando \u2013 NCT07037862 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Este \u00e9 um estudo do medicamento experimental ENTR-601-44 em participantes com distrofia muscular de Duchenne (DMD), uma condi\u00e7\u00e3o gen\u00e9tica rara.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In\u00edcio do estudo (estimado)<\/strong>: 2025-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclus\u00e3o prim\u00e1ria (estimada)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclus\u00e3o do estudo (estimada)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Locais<\/strong>: B\u00e9lgica, It\u00e1lia, Espanha, Reino Unido.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Idades eleg\u00edveis para estudo<\/strong>: 4 anos a 20 anos (crian\u00e7a, adulto)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principais crit\u00e9rios de inclus\u00e3o e exclus\u00e3o. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07037862\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07037862<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-45-skipping-nct-07038824\">Entrada Exon 45 pulando \u2013 NCT07038824 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Este \u00e9 um estudo do medicamento experimental ENTR-601-45 em participantes com distrofia muscular de Duchenne (DMD), uma condi\u00e7\u00e3o gen\u00e9tica rara.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In\u00edcio do estudo (estimado)<\/strong>: 2025-09-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclus\u00e3o prim\u00e1ria (estimada)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclus\u00e3o do estudo (estimada)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Locais<\/strong>: B\u00e9lgica, It\u00e1lia, Holanda, Espanha, Reino Unido.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Idades eleg\u00edveis para estudo<\/strong>: 4 anos a 20 anos (crian\u00e7a, adulto)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principais crit\u00e9rios de inclus\u00e3o e exclus\u00e3o. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07038824\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07038824<\/a> \u2013<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/dmdwarrior.com\/pt\/tag\/entrada-therapeutics\/\">Saiba mais sobre Entrada Therapeutics<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45\u2014marking a significant milestone in the treatment of Duchenne muscular dystrophy (DMD). These investigational therapies are designed to address specific genetic mutations in DMD patients, with the goal of restoring dystrophin production and improving clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4021,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[242,233,234,84,246,319,178],"class_list":["post-4013","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trials","tag-entrada","tag-entrada-therapeutics","tag-europe","tag-exon-44-skipping-therapies","tag-exon-45-skipping-therapy","tag-exon-skipping-therapies"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=4013"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/4021"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=4013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=4013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=4013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}